mrr pvt. Ltd.

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024

Press Release   •   Jan 13, 2017 14:47 IST

p { margin-bottom: 0.25cm; line-height: 120%; }a:link { }

OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024


Initially considered a curable disease due to substantial sensitivity to first-line chemotherapies, small cell lung cancer (SCLC) remains a fatal disease with poor outcomes due to high relapse rates, with the majority of patients surviving one year or less after diagnosis. Unlike non-small cell lung cancer (NSCLC), in which major advances in treatment have been made following the approval of several targeted therapies, the field of SCLC has seen little advancement for several decades.

For the purposes of this report, GlobalData considers the Global SCLC market to include SCLC-specific drug sales in the 7MM (US, 5EU [France, Germany Italy, Spain, and the UK], and Japan). The current market across these countries is dominated by the sale of major generic chemotherapy regimens. GlobalData estimated that the Global SCLC market was valued at $198m in 2014. Following the expected approval of new agents over the forecast period, relapsed/refractory patients will have significantly improved therapeutic options leading to rapid uptake of these drugs. The increased use of branded therapies in treatment-nave and advanced patients, such as Yervoy, Opdivo, roniciclib, and sacituzumab govitecan, will be the primary driver of the substantial growth in the SCLC market over the forecast period, which is expected to grow at a positive CAGR of almost 28% in the 7MM.


Key Questions Answered

- Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the SCLC marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2014-2024)?

- What research and development (R&D) strategies will companies leverage to compete in the future SCLC marketplace?

- Which pipeline products are poised to make a major clinical and commercial impact?

- What clinical and commercial factors are likely to influence SCLC drug uptake in the 7MM?

Download Sample Copy of This Report at: